These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31319151)

  • 41. Systemic adverse effects of topical ocular treatments.
    Labetoulle M; Frau E; Le Jeunne C
    Presse Med; 2005 Apr; 34(8):589-95. PubMed ID: 15962500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Study of Ocular Pharmacokinetics of Gatifloxacin Between Continuous Lavage and Hourly Topical Instillation in Rabbits.
    Zhao X; Shen X; Zhang X; Chen S; Lu H; Wang M
    Cornea; 2018 Nov; 37(11):1457-1462. PubMed ID: 30124589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
    Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
    Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular Route.
    Dumouchel JL; Chemuturi N; Milton MN; Camenisch G; Chastain J; Walles M; Sasseville V; Gunduz M; Iyer GR; Argikar UA
    Drug Metab Dispos; 2018 Nov; 46(11):1670-1683. PubMed ID: 30111625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thermosensitive glycol chitosan-based hydrogel as a topical ocular drug delivery system for enhanced ocular bioavailability.
    Shi H; Wang Y; Bao Z; Lin D; Liu H; Yu A; Lei L; Li X; Xu X
    Int J Pharm; 2019 Oct; 570():118688. PubMed ID: 31513870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
    Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations.
    Almeida H; Amaral MH; Lobão P; Lobo JM
    Drug Discov Today; 2014 Apr; 19(4):400-12. PubMed ID: 24120893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polymer-based carriers for ophthalmic drug delivery.
    Imperiale JC; Acosta GB; Sosnik A
    J Control Release; 2018 Sep; 285():106-141. PubMed ID: 29964135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of xenobiotic transporters in ophthalmic drug delivery.
    Chemuturi N; Yanez JA
    J Pharm Pharm Sci; 2013; 16(5):683-707. PubMed ID: 24393552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bioavailability of drugs applied to the eye externally].
    Sieradzki E
    Klin Oczna; 1991 Jan; 93(1):34-6. PubMed ID: 2046287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model.
    Moosa RM; Choonara YE; du Toit LC; Tomar LK; Tyagi C; Kumar P; Carmichael TR; Pillay V
    Int J Pharm; 2014 May; 466(1-2):296-306. PubMed ID: 24607446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Corneal penetration and ocular bioavailability of drugs.
    Burstein NL; Anderson JA
    J Ocul Pharmacol; 1985; 1(3):309-26. PubMed ID: 3916851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ocular drug delivery-eye on innovation.
    Rupenthal ID; O'Rourke M
    Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
    [No Abstract]   [Full Text] [Related]  

  • 57. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
    Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
    Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes.
    Missel PJ
    Pharm Res; 2012 Dec; 29(12):3251-72. PubMed ID: 22752935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension.
    Scoper SV; Kabat AG; Owen GR; Stroman DW; Kabra BP; Faulkner R; Kulshreshtha AK; Rusk C; Bell B; Jamison T; Bernal-Perez LF; Brooks AC; Nguyen VA
    Adv Ther; 2008 Feb; 25(2):77-88. PubMed ID: 18309465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized phase I clinical study of cis-urocanic acid eye drops in healthy adult subjects.
    Jauhonen HM; Kari E; Pylkkänen L; Poutanen J; Laihia J; Kaarniranta K; Leino L
    Acta Ophthalmol; 2015 Jun; 93(4):368-76. PubMed ID: 25611308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.